Archive | Clinical Diagnostics and Tools

buy brand provigil online We will report important news in clinical diagnostics and life science tools as it affects our portfolio.The top market sectors are sequencing and molecular diagnostics.

Roche Bid for Illumina (ILMN) Drives Biotech Sector to New Highs

source link M&A Theme Provides Underlying Bid to Market Roche Holding, the most diversified diagnostics and pharmaceutical Company with an aggressive leveraged strategy for the molecular basis of disease and personalized medicine has offered $5.7B for the leading Company in genetic sequencing and life science tools with revenues in the $1B range. The offer was $44.50 but […]

Continue Reading 0

“January Effect” Rally: A Cliched Trade That Really Works

buy Pregabalin cheap You read about it every year, and always there are skeptics, but in Q4 2011 to Q 2012 the “January effect ” rally for small cap and life science stocks were big winners. Why does this happen? Not so important just that it does happen. Here are our December focus picks (see earlier posts):   […]

Continue Reading 0

JPMorgan Healthcare Conference: Life Science Tools Rally

Life Science stocks got a boost from news and presentations at the J.P.Morgan Healthcare Conference and most stocks from the Rayno Life Science Portfolio were up.(see our “January Effect” trades mentioned in December). Leading life science tools companies Illumina (ILMN $34) up 3% again today,and Life Technologies (LIFE $46.28) were boosted by new product announcements, new […]

Continue Reading 0

Biotechnology Stock Review 2011:Update 1/2/12

Here are some key points from our 2011 Biotech Stock Review posted in Investor Uprising: Winners from the 2011 Rayno Life Science Portfolio: Abaxis (ABAX), Alexion(ALXN), Amgen (AMGN), Biogen(BIIB), Bristol-Myers (BMY),Celera(acquired),Cephalon (acquired) Cubist (CBST), Exact Scientific (EXAS),Gilead (GILD), BioETF (IBB), Immucor (acquired), Neogen (NEOG), Regeneron (REGN),Quidel (QDEL), Seattle Genetics (SGEN), United Therapeutics(UTHR) and Viropharma (VPHM) Losers: Alere […]

Continue Reading 0

Rayno Diagnostics and Tools Portfolio: ILMN, NEOG

Life Sciences: Biopharmaceutical Stocks are Hot, Tools and DX are Not We recommended avoiding the Tools/Dx sector several weeks ago as they were lagging biopharmaceutical stocks due to earnings misses, concerns about NIH finding for R&D, and lack of exciting new products. Illumina (ILMN $28.95) is up 6.5% today and has been volatile in the […]

Continue Reading 0

Rayno Life Science Portfolio: Tools Rally- A, LIFE, ILMN, QGEN

Illumina (ILMN $30.23) shares spiked today on takeover speculation. The shares were whacked in July and the stock is down 52% YTD on an earnings miss with no guidance. Revenue estimates from analysts are in the $1B range for 2011 so with the current Market Cap of $3.7B  the Company is not too expensive for […]

Continue Reading 0

Pure Play Diagnostics Roster: Metrics with Q3 Earnings

No new buys, currently on HOLD list: ABAX, EXAS, NEOG, QDEL, SRLS. Rayno Life Science Tools And Dx Portfolio Update:Immucor Beats 6/20 update | Raygent.com Outperformers YTD: ABAX up 2.9%,CPHD up 51%, EXAS up 42%, GHDX up 31%, GPRO up 9%, LMNX up 13%, QDEL up 25%, TECH up 1.5%. Underperformers YTD: ALR down 36%, […]

Continue Reading 0

Collateral Damage from Illumina (ILMN) Warning: Looking For New Buys

11/21/11 The diagnostics and tools sector remain weak trading down about 1.9%  slightly better than NASDAQ down 2.5%. Within the life sciences we prefer biopharmaceutical stocks because of M&A potential and less sensitivity to earnings. From October 11,2011 Despite a nice rally yesterday we are still cautious on the tools and diagnostics sector. Within the […]

Continue Reading 0

Investor Uprising – Guide to Biotech Investing

There is an excellent Guide to Biotech Investing on the Investor Uprising blog.  You will need a IU account to view the document  http://www.investoruprising.com/document.asp?doc_id=206689  

Continue Reading 0

Healthcare and Biotech for Relative Safety: ALXN, REGN, OPTR, SGEN

A Place to Hide from Volatility Today was not as bad as early futures and European markets would portend. The S&P cut its losses to 0.74% and the NASDAQ was down only 0.26%. But as we recommended last month the healthcare sector looks good for relative safety. Drug stocks that pay dividends and large cap […]

Continue Reading